4.42
4.42 (0%)
As of Apr 17, 2025
Olema Pharmaceuticals, Inc. [OLMA]
Source:
Company Overview
Olema is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next generation targeted therapies for breast cancer and beyond. We are advancing our pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance.
| Country | United States |
| Headquarters | san francisco, california |
| Phone Number | ( 415 ) 651-3316 |
| Industry | manufacturing |
| CEO | Sean Bohen |
| Website | www.olema.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-142.3 |
| Net Income | $-129.5 |
| Net Cash | $70.9 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -35.6% |
| Profit as % of Stockholder Equity | -31.7% |
Management Effectiveness
| Return on Equity | -31.7% |
| Return on Assets | -28.7% |
| Turnover Ratio | |
| EBITA | $-142.3 |
Balance Sheet and Cash Flow Measures
| Total Assets | $451 |
| Total Liabilities | $42 |
| Operating Cash Flow | $-104.4 |
| Investing Cash Flow | $-93.5 |
| Financing Cash Flow | $268.8 |
